相关实验视频

Updated: Jun 13, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

导航补充途径以优化PNH治疗Pegcetacoplan和其他目前批准的补充抑制剂

Peter Hillmen¹, Regina Horneff², Michael Yeh¹

¹Apellis Pharmaceuticals, Inc., Waltham, MA 02451, USA.

International journal of molecular sciences

|September 14, 2024

概括

阴性夜间血红蛋白尿 (PNH) 是一种罕见的血液疾病,由PIGA基因突变引起. 治疗的目标是补充通路,重点是C3 / C3b抑制剂,如PNH的佩格塞塔科普兰.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

阴性夜间血红蛋白尿 (PNH) 是一种罕见的,危及生命的血液学疾病.
由PIGA基因的体质突变引起,导致血液细胞上的CD55/CD59表达缺陷.
缺乏导致补充介导的血液溶解,贫血和血栓形成.

研究的目的:

审查补充剂抑制剂对PNH的作用机制.
专注于针对C3/C3b的治疗方法,特别是基甲基.
通过治疗概况,提供有关PNH分子基础的见解.

主要方法:

对当前PNH治疗方法的叙述性审查.
在C5,C3和替代途径启动水平上对补体抑制的分析.
专注于已批准的PNH疗法,包括C5抑制剂,C3/C3b抑制剂和B/D因子抑制剂.

主要成果:

目前有6种补剂抑制剂被批准用于PNH.
治疗针对补充激活途径中的不同点.
不同的治疗概况为PNH疾病控制提供了洞察力.

结论:

补充抑制剂为PNH提供了不同的治疗策略.
佩格塞塔科普兰是一种关键的C3/C3b向治疗.
了解治疗机制可以提高PNH的管理和研究.

关键词:

这是一种C3抑制剂.这是一种C5抑制剂.补充补充补充补充补充补充补充.这是一种B因子抑制剂.这是一种D因子抑制剂.阴性夜间血红素尿症.佩格塞塔科普拉纳的平面.

更多相关视频

Studying Copper Nanoparticle-Induced Programmed Cell Death in Bacteria

Studying Copper Nanoparticle-Induced Programmed Cell Death in Bacteria

Published on: May 16, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...